Nanobiotix Reports Promising JNJ-1900 Results, Strengthens Financial Position
Nanobiotix has revealed promising results from multiple clinical studies involving its lead product candidate, JNJ-1900 (NBTXR3). The company has also strengthened its financial position and expanded its intellectual property portfolio.
The University of Texas MD Anderson Cancer Center completed a dose escalation study of JNJ-1900 as a second-line therapy for locally advanced NSCLC, with initial data now available. Additionally, a Phase 1 study in primary cutaneous melanoma resistant to anti-PD-1 and another in recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have shown encouraging results when JNJ-1900 is used in combination with immune checkpoint inhibitors.
Regulatory bodies in major European countries have agreed to reclassify JNJ-1900 from a medical device to a drug, harmonizing its regulatory status. The company is also in discussions regarding non-dilutive financing to extend its cash runway beyond mid-2026. Nanobiotix has filed a new composition of matter patent for JNJ-1900 to reinforce its intellectual property foundation.
The CONVERGE study, sponsored by Johnson & Johnson, has dosed its first patient. This Phase 2 trial is evaluating JNJ-1900 in combination with standard of care chemoradiation and consolidation durvalumab for patients with Stage 3 unresectable non-small cell lung cancer. Meanwhile, the MD Anderson Phase 1 study in pancreatic cancer has been expanded following the completion of its initial cohort.
Nanobiotix's latest clinical data and regulatory harmonization support JNJ-1900's potential as a combination therapy in various cancer types. The company's strengthened financial position and expanded intellectual property portfolio further bolster its prospects.
Read also:
- Impact of a Government Shutdown on Citizens
- Medical Specialist Based in Visakhapatnam
- Individuals in New York afflicted by Legionnaires' disease have legitimate legal entitlements. Here's some essential information on the matter.
- Toxic Shock Syndrome: Signs, Origins, Tampon Connection, and Further Details
